{
    "clinical_study": {
        "@rank": "117591", 
        "acronym": "NI-0101-01", 
        "arm_group": [
            {
                "arm_group_label": "NI-0101", 
                "arm_group_type": "Experimental", 
                "description": "NI-0101 is an anti-Toll-like receptor monoclonal antibody."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The placebo to be used for the proposed clinical trial is a sterile solution for intravenous infusion. The placebo is identical to the NI-0101 drug product but does not include the active substance."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety, tolerability and distribution and\n      elimination of a novel therapeutic drug when administered to Healthy Volunteers.  In\n      addition its effects on some inflammatory parameters will be measured in presence or absence\n      of lipopolysaccharide stimulation."
        }, 
        "brief_title": "First in Human Study of an Anti-Toll-like Receptor 4 (TLR4) Monoclonal Antibody (NI-0101) in Adult Healthy Volunteers", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy adults between 18 and 40 years old (inclusive) having a body mass index (BMI)\n             between 18 and 30 kg/m2 (inclusive), able to adhere to study protocol requirements\n             and having signed  informed consent.\n\n        Exclusion Criteria:\n\n          -  Any abnormal past or present clinically relevant  medical history or  any relevant\n             abnormal laboratory parameters at screening that will prevent to consider the\n             volunteers as healthy for the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01808469", 
            "org_study_id": "NI-0101-01_"
        }, 
        "intervention": {
            "arm_group_label": [
                "NI-0101", 
                "Placebo"
            ], 
            "intervention_name": "Monoclonal antibody", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins", 
                "Antibodies, Monoclonal"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Leiden", 
                    "country": "Netherlands", 
                    "zip": "2333 CL"
                }, 
                "name": "Centre for Human Drug Research"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double Blind, Placebo-controlled, Pharmacokinetics/Pharmacodynamics-guided, Phase I Study in Healthy Volunteers Given Escalating, Single Intravenous Doses of NI-0101 in the Absence and Then in the Presence of a Systemic Lipopolysaccharide Challenge.", 
        "overall_contact": {
            "email": "emonnet@novimmune.com", 
            "last_name": "Emmanuel Monnet", 
            "phone": "+41 22 593 82 33"
        }, 
        "overall_official": {
            "affiliation": "Centre for Human Drug Research, Leiden, The Netherlands", 
            "last_name": "J. Koos Prof. Burggraaf, MD, Ph", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "12 lead ECG\nVital signs\nPhysical examination\nAdverse events\nRoutine laboratory assessments\nduring 8 weeks post administration.", 
            "measure": "Safety and tolerability of NI-0101 in healthy male/female subjects", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01808469"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Blood samples for plasma NI-0101 concentrations.\nThe following pharmacokinetic parameters of NI-0101 will be measured:\nArea under the curve from the time of dosing extrapolated to infinity (AUCinf); Area under curve from the time of dosing to the last measurable concentration (AUClast); AUCinf - AUClast expressed in % of AUCinf (% AUCextr); Systemic drug clearance (CL); Mean residence time (MRT) extrapolated to infinity (MRTinf); Mean residence time (MRT) at last measurable concentration (MRTlast).", 
                "measure": "Pharmacokinetic parameters of NI-0101", 
                "safety_issue": "No", 
                "time_frame": "Up to 8 weeks"
            }, 
            {
                "description": "Blood samples for inflammatory markers measured in blood with or without the presence of an exogenous stimulus (lipopolysaccharide).\nCytokine levels induced by ex vivo lipopolysaccharide challenge and circulating cytokine levels induced by in vivo lipopolysaccharide challenge will be measured.", 
                "measure": "Pharmacodynamic parameters of NI-0101", 
                "safety_issue": "No", 
                "time_frame": "Up to 8 weeks"
            }
        ], 
        "source": "NovImmune SA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "NovImmune SA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}